Quantinno Capital Management LP lifted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 103.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,555 shares of the company’s stock after acquiring an additional 13,507 shares during the period. Quantinno Capital Management LP owned 0.09% of Inspire Medical Systems worth $1,370,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wellington Management Group LLP bought a new position in Inspire Medical Systems during the fourth quarter valued at approximately $203,929,000. M&T Bank Corp purchased a new position in Inspire Medical Systems during the fourth quarter worth $85,871,000. Deerfield Management Company L.P. grew its holdings in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the last quarter. Morgan Stanley grew its stake in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after buying an additional 809,121 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. purchased a new stake in Inspire Medical Systems in the fourth quarter worth $61,619,000. Institutional investors own 94.91% of the company’s stock.
Analyst Upgrades and Downgrades
INSP has been the topic of a number of research reports. Truist Financial reaffirmed a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Mizuho lifted their target price on Inspire Medical Systems from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Evercore set a $54.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems has an average rating of “Hold” and a consensus target price of $68.00.
Inspire Medical Systems Stock Performance
Shares of INSP opened at $58.24 on Friday. The stock has a 50-day moving average of $49.06 and a two-hundred day moving average of $53.44. The stock has a market cap of $1.68 billion, a P/E ratio of 12.61, a P/E/G ratio of 4.43 and a beta of 0.70. Inspire Medical Systems, Inc. has a one year low of $38.91 and a one year high of $147.03.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period last year, the business posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Analysts predict that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Jason P. Kelly sold 963 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.20% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Read More
- Five stocks we like better than Inspire Medical Systems
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
